Open AccessConversion of cardiac and liver transplant recipients from HPLC and FPIA (polyclonal) to an FPIA (monoclonal) technique for measurement of blood cyclosporin A
Author(s) -
McBride James H.,
Kim Steaven,
Rodgerson Denis O.,
Reyes Ana
Publication year - 1998
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/(sici)1098-2825(1998)12:6<337::aid-jcla2>3.0.co;2-d
Subject(s) - monoclonal , polyclonal antibodies , monoclonal antibody , transplantation , whole blood , liver transplantation , high performance liquid chromatography , medicine , chemistry , chromatography , immunology , antibody
In an effort to replace HPLC and FPIA (polyclonal) for whole blood determination of Cyclosporin A (CsA), this study examined the application of FPIA (monoclonal) in patients post cardiac and liver transplantation. The assay had a minimum detectable dose of 15μg/ L, an overall recovery of 97% and was linear to 1200μg/ L, and gave inter‐assay precision values of < 5% (CV). On comparing FPIA (monoclonal) and HPLC for 59 cardiac transplant recipient blood samples, a correlation of FPIA (monoclonal) = 1.30 (HPLC) + 36.34, r = 0.96 was obtained. With liver transplant samples (n = 348), the correlation was FPIA (monoclonal) = 1.21 (HPLC) + 42.15, r = 0.98. Correlation on 131 cardiac transplant recipients gave FPIA (monoclonal) = 0.31 FPIA (polyclonal) + 43.97, r = 0.68. It is concluded that when converting from HPLC to FPIA (monoclonal) a positive bias of 21%–30% is observed, and in replacing FPIA (polyclonal) with FPIA (monoclonal), a negative bias of 50%–69% is seen with liver and cardiac patients respectively. These data indicate that therapeutic ranges should be reestablished or adjustments in CsA dosing would be necessary. J. Clin. Lab. Anal. 12:337–342, 1998. © 1998 Wiley‐Liss, Inc.